ACIP Human Rabies Prevention Work Group by Frey, Sharon et al.
National Center for Emerging and Zoonotic Infectious Diseases
ACIP Human Rabies Prevention Work Group 
Sharon Frey, MD
Saint Louis University School of Medicine
Advisory Committee on Immunization Practices
October 23, 2019
Work Group Members
ACIP Members
Sharon Frey (chair)
Lynn Bahta
José R. Romero
Liaison Representatives
AAP- Elizabeth Bennett
AAFP- James Stevermer
NACCHO- Matt Zahn
APhA- Karl Hess
NACI- Julie Emili and Linlu Zhao
FDA- Paula Agger and Robin Levis
NASPHV- Katie Brown and Sally Slavinski
APHL-Michael Pentella
Travel medicine- David Shlim
Additional Subject Matter Experts
Susan Moore
Deborah Briggs
CDC
Rabies Work Group leads – Jesse Blanton 
and Agam Rao
Division of Global Migration and 
Quarantine- Kristina Angelo
Immunization Safety Office – Pedro Moro
Acknowledgements
CDC Technical Work Group and 
Subject Matter Experts
Brett Petersen
Ryan Wallace
James Ellison
Sathesh Panayampalli
Anna Mandra
Jesse Bonwitt
Erin Whitehouse
Terms of Reference  Abbreviated
 Determine the epidemiology and burden of rabies exposures 
and PreP and PEP administration in the United States
 Evaluate and revise recommendations as needed for 
vaccination schedules,  route and site of PrEP and PEP, and 
cost-effectiveness
 Consider evidence generated to inform the rabies 
recommendations of other global organizations 
 Review rabies exposure risk and risk assessment guidelines for 
the general population and by occupational and recreational 
groups
Terms of Reference Continued
 Evaluate serological and monitoring recommendations including 
whether recommendations should differ depending on the degree 
of rabies risk for a person and whether adequate antibody titers are 
needed to confirm immunization
 Consider whether recommendations should differ for healthy adults 
compared to immunocompromised persons and pregnant women
 Update recommendations with information about the 2 rabies 
immune globulin products approved by the US FDA during 2018
 Identify areas in need of further research for informing future 
vaccine and immune globulin recommendations
Timeline (Subject to Change)
PHASE I PHASE II PHASE IV PHASE V
CDC: Determine 
scope 
Begin systematic 
reviews 
Begin Work 
Group meetings
Update 
Guideline Recs
Mid 2018 October 2018
October 2019 
to 2020 2020 or 
2021?
Begin presenting 
to ACIP
PHASE III
Tentative Plan for Presentations
 October 2019 – Background and introduction to PrEP issues
 February 2020  
–
–
–
–
–
Detailed PrEP data including GRADE table 
Introduction to PEP issues
 June 2020
Vote for PrEP topics
More detailed presentations about PEP
 October 2020
More detailed presentations about PEP vs. vote on PEP issues
Note:  Current Rabies Vaccine and Immune Globulin 
Shortages
 The shortages should not impact patient care.  Vaccine and RIG available 
for every patient who needs it.  No modification to current practices.
 Vaccine
–
–
–
–
RabAvert (GlaxoSmithKline):  available directly from the manufacturer
Imovax® (Sanofi Pasteur):  Currently unavailable but expected to be 
available late Oct / early Nov
 RIG
Imogam® (Sanofi Pasteur):  available directly from manufacturer
Kedrab™ (Kedrion Biopharma) and HyperRab® (Grifols):  unchanged 
availability and no difficulties filling gap from Imogam
For more information: https://www.cdc.gov/rabies/resources/availability.html
October 21, 2019 GlaxoSmithKline Announcement
 GSK divesting rabies vaccine (RabAvert in U.S.) to Bavarian 
Nordic
 Vaccine will continue to be manufactured primarily at GSK’s 
Marburg, Germany site until full production is transferred to 
Bavarian Nordic
 No immediate impact to vaccine supply
Overview of Today’s Session
 Background - Dr. Agam Rao (CDC/NCEZID)
 Introduction to rabies PrEP schedule and serological 
monitoring by risk category in healthy nonpregnant persons 
and special populations - Dr. Jesse Blanton (CDC/NCEZID)
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Thank you!
